Combination antibody therapy shows promise in metastatic melanoma
A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators. The findings (abstract 8511), will be presented in an oral session at the annual meeting of the American Society of Clinical Oncology on Saturday, June 4, 3 p.m. CT, Arie Crown Theater, McCormick Place.
The drugs -- ipilimumab and bevacizumab -- are both monoclonal antibodies, intensified formulations of natural disease-fighting proteins. Ipilimumab spurs the immune system to attack diseased cells, including tumor cells. Bevacizumab, also known by the trade name Avastin, blocks the growth of blood vessels that provide tumors with nourishment. Ipilimumab has extended the lives of metastatic melanoma patients in previous clinical trials, and bevacizumab is often used to treat tumors of the colon, lung, and kidney.
The trial involved 22 patients with metatastic melanoma that was not treatable by surgery.
F. Stephen Hodi, MD, the study's lead author and director of the melanoma treatment center at Dana-Farber, said the trial is the first to explore whether the two agents enhance each other's effectiveness. Most of the participants didn't experience serious adverse side effects, although some did experience inflammation of artery walls, the liver, thyroid gland, colon, or uvea (the middle layer of the eye). Five patients required steroid treatment for these problems and were removed the trial.
Positron emission tomography (PET) scans showed a prompt immune system response to many of the melanoma tumors, and computed tomography (CT) scans showed decreased blood flow to the tumors. Eight of the participants had partial responses -- showing some tumor shrinkage -- to the dual treatment, and six had stable disease. All the responses lasted at least six months. Biopsies performed after the treatment showed a more vigorous immune system response than would be expected with ipilimumab alone.
"Our findings indicate that ipilimumab and bevacizumab can be safely administered with careful management of side effects," said Hodi. "The results of lab tests suggest that the two agents may work synergistically, with 14 of 21 evaluable patients experiencing a clinical benefit. This approach merits exploration in further clinical trials."
Source: Dana-Farber Cancer Institute
Articles on the same topic
- Vaccine first to show improved survival rates for metastatic melanomaSun, 5 Jun 2011, 19:33:39 UTC
- Study finds vaccine extends recurrent GBM survival rates by 2 to 3 timesFri, 3 Jun 2011, 15:37:05 UTC
- Therapeutic melanoma vaccine improves response rate, progression-free survivalThu, 2 Jun 2011, 13:04:31 UTC
- Vaccine increases disease-free survival for follicular lymphoma patients Tue, 31 May 2011, 23:42:44 UTC
Other sources
- 2 new drugs a 'major breakthrough' in treating deadly skin cancerfrom LA Times - ScienceSun, 5 Jun 2011, 19:30:31 UTC
- Studies Find New Drugs Boost Skin Cancer Survivalfrom NY Times HealthSun, 5 Jun 2011, 15:50:11 UTC
- Melanoma Drug Combo Shows Promise in Early Trialfrom Science NOWSat, 4 Jun 2011, 19:10:06 UTC
- Popular Drug Stalls Ovarian Cancer, Studies Sayfrom NY Times HealthSat, 4 Jun 2011, 17:00:13 UTC
- Combination antibody therapy shows promise in metastatic melanomafrom PhysorgSat, 4 Jun 2011, 6:00:57 UTC
- Combination antibody therapy shows promise in metastatic melanomafrom Science BlogSat, 4 Jun 2011, 0:31:05 UTC
- Combination antibody therapy shows promise in metastatic melanomafrom Science DailyFri, 3 Jun 2011, 23:30:27 UTC
- Combination antibody therapy shows promise in metastatic melanomafrom Science BlogFri, 3 Jun 2011, 22:00:35 UTC
- Vaccine extends recurrent glioblastoma survival rates by 2 to 3 times, study findsfrom Science DailyFri, 3 Jun 2011, 16:30:55 UTC
- Therapeutic melanoma vaccine improves response rate, progression-free survival, study findsfrom Science DailyThu, 2 Jun 2011, 15:30:30 UTC
- Therapeutic melanoma vaccine improves response rate, progression-free survivalfrom PhysorgThu, 2 Jun 2011, 14:00:38 UTC
- Vaccine increases disease-free survival for follicular lymphoma patients: Study on personalized therapy may lead to a 'flood of new agents'from Science DailyTue, 31 May 2011, 23:30:31 UTC
- Vaccine increases disease-free survival for follicular lymphoma patientsfrom PhysorgTue, 31 May 2011, 20:31:38 UTC